Dendritic Compounds as Immune Response Modulators. New Approaches for Vaccine Development

J. Rojo
{"title":"Dendritic Compounds as Immune Response Modulators. New Approaches for Vaccine Development","authors":"J. Rojo","doi":"10.2174/187152109787047832","DOIUrl":null,"url":null,"abstract":"Despite several infectious diseases which have been eradicated or controlled worldwide nowa- days, there are still some infectious diseases such as AIDS, caused by HIV, which are supposed to be a se- rious social health problem and demand the search for new vaccines. A classical approach for generation of vaccines against infection was initially based on the use of killed or attenuated pathogens. With the in- crease of information about mechanisms governing immune responses after microorganism infection, new approaches have been investigated. The use of dendritic cells (DCs) pulsed with whole pathogen organ- isms has been considered and explored; however, this approach still presents serious concerns about safety issues. This fact has conducted to a \"non-classical\" approach where well defined antigens with complete control of mo- lecular design are used. Two strategies are generally envisaged. One is based on the direct stimulation of T and B-cells us- ing immunogenic peptides for producing antibodies and the other one is based on the use of antigen-pulsed dendritic cells producing both cellular and humoral response. This review will be focused on the state of the art of these new approaches for vaccine development to infectious diseases. Synthetic strategies, technical problems, and applications of multivalent dendritic systems will be described and com- mented. This is a topic of enormous interest which could open interesting alternatives and expectancy in infectious dis- eases for the development of effective therapies.","PeriodicalId":89320,"journal":{"name":"Anti-infective agents in medicinal chemistry","volume":"4 1","pages":"50-72"},"PeriodicalIF":0.0000,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/187152109787047832","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-infective agents in medicinal chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/187152109787047832","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12

Abstract

Despite several infectious diseases which have been eradicated or controlled worldwide nowa- days, there are still some infectious diseases such as AIDS, caused by HIV, which are supposed to be a se- rious social health problem and demand the search for new vaccines. A classical approach for generation of vaccines against infection was initially based on the use of killed or attenuated pathogens. With the in- crease of information about mechanisms governing immune responses after microorganism infection, new approaches have been investigated. The use of dendritic cells (DCs) pulsed with whole pathogen organ- isms has been considered and explored; however, this approach still presents serious concerns about safety issues. This fact has conducted to a "non-classical" approach where well defined antigens with complete control of mo- lecular design are used. Two strategies are generally envisaged. One is based on the direct stimulation of T and B-cells us- ing immunogenic peptides for producing antibodies and the other one is based on the use of antigen-pulsed dendritic cells producing both cellular and humoral response. This review will be focused on the state of the art of these new approaches for vaccine development to infectious diseases. Synthetic strategies, technical problems, and applications of multivalent dendritic systems will be described and com- mented. This is a topic of enormous interest which could open interesting alternatives and expectancy in infectious dis- eases for the development of effective therapies.
树突状化合物作为免疫反应调节剂。疫苗开发的新途径
尽管当今世界上有几种传染病已经被根除或控制,但仍有一些传染病,如艾滋病,由艾滋病毒引起,被认为是一个严重的社会健康问题,需要寻找新的疫苗。生产抗感染疫苗的经典方法最初是基于使用杀死或减毒的病原体。随着对微生物感染后免疫应答机制的了解不断增加,人们开始探索新的途径。树突状细胞(dc)与整个病原体器官脉冲的使用已被考虑和探索;然而,这种方法仍然存在严重的安全问题。这一事实导致了一种“非经典”方法,即使用完全控制分子设计的明确抗原。一般设想了两种战略。一种是基于直接刺激T细胞和b细胞产生抗体的免疫原性肽,另一种是基于使用抗原脉冲树突状细胞产生细胞和体液反应。本文将重点介绍这些传染病疫苗开发新方法的最新进展。本文将描述和评论多价枝晶体系的合成策略、技术问题和应用。这是一个非常有趣的话题,它可以为感染性疾病的有效治疗开辟有趣的选择和期望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书